Lumibird 股票：股价与高管交易 · 法国

Operationally, Lumibird is organized around two complementary divisions. The Photonics division serves scientific, industrial and defense markets with high-performance laser sources, rangefinders, sensors and electro-optical systems. The Medical division brings together the Quantel Medical, Ellex and Optotek Medical brands, offering diagnostic and therapeutic laser solutions for ophthalmology. This structure gives the group a balanced exposure to different demand drivers, combining innovation-intensive niche markets with recurring medical applications and defense-related opportunities.

Lumibird operates an integrated industrial model, supported by research, manufacturing and sales capabilities across 14 countries. The company states that it employs around 1,000 people, with 12 R&D sites, 10 production sites and 15 commercial subsidiaries. Its historical base remains in Lannion, Brittany, but its industrial footprint and customer base are international. In 2025, the group reported annual revenue of €225.6 million, up 8.9% as reported and 10.2% at constant scope and exchange rates, confirming solid momentum across both divisions.

A noteworthy feature of Lumibird is its positioning in highly technical, innovation-driven markets where technological depth and industrial reliability are critical competitive advantages. The group has also highlighted defense-related contract wins in 2025 and 2026, underscoring the increasing strategic importance of this segment within its revenue mix. Overall, Lumibird combines a strong French industrial heritage, a global commercial footprint and a differentiated expertise in laser technologies.